US-based ClearNote Health has started subject enrolment in a multi-centre, prospective study in the UK involving its Avantect pancreatic cancer test, to enhance early detection among individuals newly diagnosed with type 2 diabetes (T2D).
The University Hospital Southampton National Health Service (NHS) Foundation Trust sponsored this study, with participation expected from up to 15,000 patients.
The SAFE-D study will be spearheaded by University Hospital Southampton consultant pancreatic cancer surgeon Zaed Hamady.
It will be carried out by researchers at the Southampton Clinical Trials Unit (CTU) at the University of Southampton, UK.
The study will also offer additional prospective validation data for the blood test and aid in identifying early signals of pancreatic cancer present in the elevated-risk group.
The Avantect Pancreatic Cancer Test targets individuals at risk, particularly those above 50 years of age who have been newly diagnosed with T2D, those with a family history of the disease, or with a genetic predisposition.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt claims to analyse the epigenomic biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA, along with other genomic data, to identify the cancer at its most treatable stages.
ClearNote Health chief scientific officer Samuel Levy said: 鈥淓arly detection is the key to saving lives from the deadliest cancers.
鈥淲e intend to demonstrate that the Avantect test can identify pancreatic cancer in stages I and II, and we鈥檙e thrilled to be part of this transformative study that could redefine how pancreatic cancer is detected and managed for patients at high risk due to a recent diabetes diagnosis.鈥�
In 2023, ClearNote Health announced that its Avantect test聽could identify pancreatic cancer聽in high-risk individuals, such as those recently diagnosed with T2D, in a trial.
